Diagnostics News and Research

RSS

Evaluating new approaches for rare disease research

Marcel Nelen discusses his team’s early evaluation of a new workflow for rare disease genomics.

From Illumina, Inc. 10 Sep 2026

Yourgene Health launches Insight DPYD assay (IVDR)

Yourgene Health (part of the Novacyt Group), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the commercial launch of its In Vitro Diagnostic Regulation (IVDR)-certified Yourgene® Insight DPYD assay, expanding the Company's clinical genetics portfolio across regulated European markets.

From Yourgene Health 9 Sep 2026

Protein-based MRI agent detects tiny lung cancer metastases

A multi-institutional research team led by Georgia State University Regents' Professor Emerita of Biochemistry and Biophysical Chemistry Jenny J. Yang has developed a new class of protein-based MRI contrast agent that detects invasive lung cancer and metastatic disease at earlier stages than conventional imaging approaches.

9 Sep 2026

New genetic map helps track aggressive prostate cancer development

Prostate cancer is the second most common form of cancer among men globally. Yet, we still know relatively little about why the disease develops or why some men live with it for years while in others it progresses aggressively.

9 Sep 2026

Digital companion apps help secure long-term habits during GLP-1 therapy

Glucagon-like peptide-1 (GLP-1) medications have revolutionized weight management, yet high dropout rates and rapid weight regain remain significant hurdles for many patients.

9 Sep 2026

New blood screening algorithm reduces unnecessary Alzheimer's PET scans

A new blood-based screening algorithm dramatically reduced the number of unnecessary PET scans needed to recruit patients at risk of Alzheimer's disease for a clinical trial, according to research from scientists at the Keck School of Medicine of USC published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

9 Sep 2026

New laser-fabricated plasmonic chip accurately identifies and sorts cancer cells

Novel laser-fabricated plasmonic chip combines 185 nm Raman resolution and deep learning to identify and sort cancer cells with 96.2% accuracy.

9 Sep 2026

Bedfont® Scientific one step closer to improving smoking cessation in Latin America

Bedfont® Scientific Limited, an innovative MedTech company with nearly 50 years of experience in the breath analysis industry, is pleased to collaborate with Medicah S.A.S through a new registration for the Smokerlyzer® range of carbon monoxide (CO) monitoring devices.

From Bedfont® Scientific Ltd 9 Sep 2026

Atherosclerosis qualifies as an autoimmune disease

A new study in mice and patients shows that atherosclerosis meets the criteria for an autoimmune disease.

7 Sep 2026

New study uncovers bacterial route to testosterone production

Many prostate cancers depend on androgen hormones, including testosterone, to grow. That is why treatments for advanced disease often try to reduce testosterone production or block its effects.

4 Sep 2026

Research reveals how natural enzymes transcribe expanded eight-letter genetic code

All known life on earth utilizes the same genetic alphabet, consisting of four letters. Now, researchers at University of California San Diego have demonstrated that one of biology's most essential enzymes can accurately read and transcribe an expanded, eight-letter genetic alphabet.

4 Sep 2026

Brain-protecting immune cells may actually drive Alzheimer's disease

Immune cells that normally protect the body from damage by attacking foreign or infected cells are found in the brains of patients with Alzheimer's disease and related disorders at much higher levels than in healthy brains.

3 Sep 2026

AI tools map tumor architecture to predict treatment response

Spatial transcriptomics is a powerful tool to create a detailed map of not just how genes are expressed in a piece of tissue, but also where genetic activity takes place in different cells and locations within the tissue.

31 Aug 2026

New dual-drug strategy blocks triple-negative breast cancer growth

Triple-negative breast cancer (TNBC) has a frustrating ability to adapt. Although this aggressive form of breast cancer can initially respond well to chemotherapy, cancer cells often find ways to survive, allowing the disease to return and become resistant to treatment.

31 Aug 2026